TABLE 3

Stratified analysis on the daily dose and lipophilicity for the association of DILI with drugs being P450 substrates, inhibitors, or inducers

The analysis is based on data shown in Supplemental Table 1. The high daily dose and high lipophilicity were previously defined (Chen et al., 2013a).

Classification	DILI-Positive	DILI-Negative	OR (95%CI)	P Value
High daily dose (≥100 mg)
P450 substrate
Yes	101	5	4.83 (1.59–14.7)	0.0029
No	46	11
P450 inhibitor
Yes	68	2	6.03 (1.32–27.5)	0.0098
No	79	14
P450 inducer
Yes	31	3	1.16 (0.31–4.32)	0.8275
No	116	13
Total	147	16	4.98 (2.55–9.76)	0.0001
Low daily dose (<100 mg)
P450 substrate
Yes	48	14	5.61 (2.15–14.6)	0.0003
No	11	18
P450 inhibitor
Yes	25	14	0.95 (0.40–2.25)	0.8997
No	34	18
P450 inducer
Yes	12	4	1.79 (0.53–6.08)	0.3509
No	47	28
Total	59	32
High lipophilicity (logP ≥3.0)
P450 substrate
Yes	73	9	3.60 (1.22–10.6)	0.0274
No	18	8
P450 inhibitor
Yes	47	8	1.20 (0.43–3.39)	0.7954
No	44	9
P450 inducer
Yes	21	1	4.80 (0.60–38.4)	0.1863
No	70	16
Total	91	17	1.44 (0.75–2.77)	0.3312
Low lipophilicity (logP <3.0)
P450 substrate
Yes	76	10	4.09 (1.76–9.54)	0.0009
No	39	21
P450 inhibitor
Yes	46	8	1.92 (0.79–4.65)	0.2081
No	69	23
P450 inducer
Yes	21	1	6.70 (0.86–51.9)	0.0459
No	94	30
Total	115	31